ArticleAmerican journal of respiratory cell and molecular biology2009
Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells.
Article in American journal of respiratory cell and molecular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.Respiratory medicine · 2015Trial
- Airway Mucosal Defense: Mucins, Innate Immunity, and Contemporary Mucoactive Strategies.Biomedicines · 2026Review
- Efficacy of EA575 as an Antitussive and Mucoactive Agent in Preclinical In Vivo Models.Biomedicines · 2025Article
- Rational use of mucoactive medications to treat pediatric airway disease.Paediatric respiratory reviews · 2020Review
- Changes to cellular water and element content induced by nucleolar stress: investigation by a cryo-correlative nano-imaging approach.Cellular and molecular life sciences : CMLS · 2013Article
- Contribution of α7 nicotinic receptor to airway epithelium dysfunction under nicotine exposure.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Exhaled breath condensate detects baseline reductions in chloride and increases in response to albuterol in cystic fibrosis patients.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2013Article
- Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis.BMC pulmonary medicine · 2012Article
- Unstressing intemperate models: how cold stress undermines mouse modeling.The Journal of experimental medicine · 2012Article
- New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.British journal of pharmacology · 2011Review
- Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.BMC gastroenterology · 2010Article
- Mucoactive drugs.European respiratory review : an official journal of the European Respiratory Society · 2010Review
- beta-Adrenoceptor inverse agonists in asthma.Current opinion in pharmacology · 2010Review
- Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.Acta pharmacologica Sinica · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activity of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) can be mediated by surface G protein-coupled receptors such as the beta(2)-adrenergic receptor. In this study, we explored the effect of a long-acting beta(2)-adrenergic agonist, salmeterol, on the CFTR-dependent secretory capacity of a human CF tracheal gland serous cell line (CF-KM4), homozygous for the delF508 mutation. We showed that, compared with the untreated CF serous cells, a 24-hour pre-incubation period with 200 nM salmeterol induced an 83% increase in delF508-CFTR-mediated chloride efflux. The restoration of the bioelectric properties is associated with increased apical surface pool of delF508-CFTR. Salmeterol induced a decrease in ion concentration and an increase in the level of hydration of the mucus packaged inside the CF secretory granules. The effects of salmeterol are not associated with a persistent production of cAMP. Western blotting on isolated secretory granules demonstrated immunoreactivity for CFTR and lysozyme. In parallel, we measured by atomic force microscopy an increased size of secretory granules isolated from CF serous cells compared with non-CF serous cells (MM39 cell line) and showed that salmeterol was able to restore a CF cell granule size similar to that of non-CF cells. To demonstrate that the salmeterol effect was a CFTR-dependent mechanism, we showed that the incubation of salmeterol-treated CF serous cells with CFTR-inh172 suppressed the restoration of normal secretory functions. The capacity of salmeterol to restore the secretory capacity of glandular serous cells suggests that it could also improve the airway mucociliary clearance in patients with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.